Navigation Links
Lilly Statement on Indiana Biosciences Research Institute
Date:5/30/2013

INDIANAPOLIS, May 30, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has issued the following statement from Senior Vice President Bart Peterson regarding today's announcement introducing the Indiana Biosciences Research Institute:

"The Indiana Biosciences Research Institute will change the bio-landscape of our region. Indiana's life sciences companies spend billions of dollars in research and development each year to advance health care innovations for improved human health. The Institute will help us nurture our partnerships across the country and develop more intellectual capital here in Indiana -- allowing us to keep more research dollars in the state, attract more federal research funds, and draw top scientific minds to feed our research pipeline and local economies.

"For years, Indiana has been a life sciences leader. We have roughly 2,000 companies, big and small, that focus on life sciences in our state. Our biopharmaceutical companies, agricultural science companies, device and diagnostic companies, and world-class universities have collectively pushed Indiana to the front of the line as a life sciences hub. Moving forward, the institute will help us tear down silos and bring our organizations together – benefitting patients who desperately need better solutions for emerging diseases and other difficult health care challenges.

"This institute is unique because Lilly and other private sector companies are partnering with state government and three major universities to support its creation – and it will make all Hoosier bioscience companies, including Lilly, even stronger.  An impressive roster of collaborators, an environment that attracts national and international talent, and an infrastructure that allows us to build a deeper library of intellectual property will separate Indiana from other states attempting to replicate our success.

"A decade ago, BioCrossroads helped Indiana become a more attractive place for life sciences companies to do business. Today, we collectively take the next step with the Indiana Biosciences Research Institute."

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information ─ for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com and https://twitter.com/LillyPad_Media. C-LLY

Refer to: (317)432-5195 (m); (317)277-4021 (o) - Greg Kueterman

(Logo:  http://photos.prnewswire.com/prnh/20031219/LLYLOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma
2. Lilly Announces CEO Dr. John Lechleiter to Undergo Scheduled Surgery
3. Lilly Declares Second-Quarter 2013 Dividend
4. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
5. The Importance of Emergency Preparedness: Lilly Diabetes and the American College of Endocrinology (ACE) Help Prep People with Diabetes for Emergencies - Big or Small
6. Lilly Diabetes and Disney Publishing Worldwide Expand Collaboration
7. Lilly Celebrates National Volunteer Week with Deployment of Global Service Teams
8. Lilly Again Named One of DiversityIncs Top 50 Companies for Diversity
9. Lilly Reports First-Quarter 2013 Results
10. Zacks Industry Outlook Highlights: Eli Lilly, Novo Nordisk, Biogen, Amgen and Osiris Therapeutics
11. Lilly Confirms Date and Conference Call for First-Quarter 2013 Financial Results Announcement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Maharashtra, February 12, 2016 ... Market research report titled Chronic Inflammation Global Clinical ... a snapshot of the global clinical trials landscape ... clinical trials by Region, Country (G7 & E7), ... point status and reviews top companies involved and ...
(Date:2/11/2016)... Feb. 11, 2016 Stem cells are primitive ... by self-renewal and the capacity to differentiate into mature ... discovery, as the first mouse embryonic stem cells were ... until 1995 that the first culturing of embryonic stem ... were not produced until 2006 As a result of ...
(Date:2/11/2016)... SAN FRANCISCO , Feb. 11, 2016  Kindred ... focused on saving and improving the lives of pets, ... Technical Section of the New Animal Drug Application (NADA) ... the pivotal field study (KB0120) of Zimeta for the ... by the Company. --> ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... February 13, 2016 , ... ... Society (INS) states that vein visualization technology should be used to ensure patient ... around the world, the INS Standards mandate the use of vein visualization technology ...
(Date:2/13/2016)... ... 13, 2016 , ... When an Au Pair comes all the way around the ... in for and they are often worried things won’t go well. More often than not, ... year’s Au Pair of the Year winner’s all commented how their Au Pairs have become ...
(Date:2/13/2016)... ... February 13, 2016 , ... DDi ... Management Solution Providers list for its expertise in eClinical Solutions. DDi has built ... serve the technology needs of global clients. DDi provides smarter technology for Clinical ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Mystic Buddha Publishing ... in Blue SKies Buddha, the biography of Rama - Dr. Frederick Lenz. ... story, the love of a Buddhist teacher for teaching and helping others. Valentine’s ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop the advanced skills needed to introduce ... from U.S. universities who will draw from Siemens’ deep knowledge of product ...
Breaking Medicine News(10 mins):